Kornimate/medical-research-clean huggingface dataset:
seprafilm™ for the prevention of intraperitoneal adhesions and improved delivery of therapy in women undergoing staging and intraperitoneal chemotherapy for advanced ovarian cancer

Conditions: Epithelial Ovarian Cancer

Summary: the purpose of this research is to determine if a film to prevent adhesions will improve the area of distribution of a contrast dye (representative of chemotherapy) in the abdominal cavity (belly) of women who have undergone surgery for ovarian cancer as compared with patients who have not had adhesion barrier sheets placed in the belly. it is believed that this film, seprafilm™, reduces adhesions (scar tissue between tissues and organs) in the abdominal cavity following surgery. adhesions can limit the distribution of the chemotherapy agent placed in the abdomen to treat the ovarian cancer. thirty subjects will receive adhesion barrier sheets and thirty will not. to determine if the sheets prevent adhesions, all subjects will have a dye inserted into the abdomen and then have x-rays of the abdomen to look at the distribution of the dye between the two groups. hypothesis: null hypothesis: there is no difference in area of distribution of the intraperitoneal dye in the seprafilm ™ vs. no seprafilm™ groups. alternative hypothesis: seprafilm™ reduces adhesion formation and there is a larger area of distribution of intraperitoneal dye in the seprafilm™ group.

the recommended treatment of epithelial ovarian cancer (eoc) includes optimal surgical debulking to \ 1 cm) or lack of/poor distribution of ip drug secondary to adhesions. any product that could be shown to decrease those adhesions and increase the area of distribution of ip therapy would prove a major advantage. the majority of scarring and adhesions take place in the first 7 days after a surgical procedure. and the first ip and iv chemotherapy usually commences between 7-21 days after surgery. therefore, the first treatment provides an opportunity to assess intraperitoneal adhesions. to assess adhesions, we will inject radiopaque dye (iohexol) via the ip port, rotate the patient per the standard practice during ip therapy to distribute the injected liquid, and then take 3 views (simple x-rays) of the abdomen. the area of distribution of the dye (representing distribution of ip chemotherapy) will be compared in two groups of subjects (seprafilm™ vs. no seprafilm™).

Eligibility criteria:
inclusion criteria: * epithelial ovarian cancer * stage iii or iv (advanced) * planned intraperitoneal chemotherapy * optimally debulked to less than 1 cm residual tumor in any area within the peritoneal cavity (after consent prior to randomization)

Keywords: adhesion barrier sheets ovarian cancer advanced stage epithelial ovarian cancer
comparison between the european and japanese pathological investigation for colon cancer (space)

Conditions: Colonic Neoplasms

Summary: in general, the european pathological examination method primarily relies on pathologists and does not require the involvement of surgeons. the japanese pathological evaluation approach, on the other hand, involves the intervention of surgeons, particularly in the extraction of lymph nodes from fresh specimens and the assessment of specimen quality. given that the japanese pathological assessment method lacks systematic evaluation and there is currently no literature clearly demonstrating its diagnostic accuracy, the main objective of this study is to verify whether the diagnostic accuracy of the japanese pathological investigation method is inferior to that of the european pathological evaluation method.


Eligibility criteria:
inclusion criteria: * patients diagnosed with colon cancer who underwent colectomy; * patients with pathological confirmed adenocarcinoma; * patients agreed to participate in the study. exclusion criteria: * patients suffered from rectal cancer; * patients diagnosed with colon cancer but did not undergo colectomy; * patients refused participation.
core stabilization training in child and adolescent underwater rugby athletes

Conditions: Core Stabilization; Trunk Muscle Endurance; Respiratory Function; Quality of Life

Summary: demographic information of children aged 9-17 who volunteer to participate in the study and who play underwater rugby will be recorded, and all participants; respiratory function will be assessed with a portable spirometer (cosmed poni fx) device, respiratory muscle strength will be assessed with a portable (micro rpm brand) electronic mouth pressure measurement device, and quality of life will be assessed with the kidscreen scale. core muscle endurance will be assessed with trunk flexion, trunk extension, lateral plank tests and flat plank test developed by mcgill. respiratory muscle strength will be measured according to ats/ers criteria using a portable electronic mouth pressure measurement device (micro rpm brand). respiratory function test will be performed using a portable spirometer (cosmed pony fx) to assess respiratory function. capillary blood oxygen saturation of children will be recorded according to pulse oximetry results. blood pressure will be measured with a cuff of appropriate size after a 5-minute rest according to age, gender and height percentile. the experimental group will receive core stabilization training in addition to the training process. this training; exercise training will be provided for 6 weeks, 3 days a week, 2 sets of 10 repetitions for the first two weeks, 2 sets of 15 repetitions for the second two weeks, and 3 sets of 12 repetitions for the third two weeks (rahmat, et al., 2014). mip/mep values will be evaluated once a week. the control group will be monitored during the training and no training program will be given. the exercise program will be applied at the end of the project by being included in the follow-up list. the children will be taken to the second evaluation 6 weeks after the first evaluation.


Eligibility criteria:
inclusion criteria: * doing underwater rugby. * no mental problems. * able to cooperate. exclusion criteria: * diagnosed with respiratory system disease. * kyphoscoliosis and/or advanced postural alignment problems that will affect respiratory function. * any orthopedic and neurological problems.
amr's maneuver and postpartum hemorrhage

Conditions: Postpartum Hemorrhage

Summary: the impacts of using amr's manoeuvre (cervical traction) on atonic postpartum hemorrhage is a randomized controlled, multi-centre study that aims to compare the incidence of post partum hemorrhage (pph\> 500 ml blood loss) within the first 24 hours of labor after using amr's maneuver with active management of the third stage versus active management alone

primary: compare the incidence of post partum hemorrhage (pph\> 500 ml blood loss) within the first 24 hours of labor after using amr's maneuver with active management of the third stage versus active management alone secondary: comparing: * the amount of blood loss in each arm of the study * hematocrit before and after labor * duration from delivery of placenta till discharge from the delivery room

Eligibility criteria:
inclusion criteria: * all pregnant females aged 18 years or more, candidate for normal vaginal delivery during the period of the study will be included exclusion criteria: * women presenting with pre-existing maternal hemorrhagic conditions such as factor 8 or 9 deficiency or von willebrand's disease or those who had assisted vaginal delivery

Keywords: postpartum hemorrhage pph atonic new maneuver
study of circulating blood cell monocytes as predictive biomarker of bone cystic fibrosis disease. impact of cftr correctors.

Conditions: Cystic Fibrosis

Summary: the aim of the study is to look for risk factors of developing osteoporosis in patients with cystic fibrosis. blood cells called monocytes will be obtained from a blood sample. these monocytes will make possible to form another class of cells called osteoclasts in the laboratory. these latter cells are responsible for bone degradation and therefore promote the increase of bone fragility. the research will focus on the characterization of these cells to better understand their potential (low, medium or high) to increase bone fragility in patients with cystic fibrosis. finally the action of cftr modulators on these bone cells will be tested.

the aim of the study is to characterize the profile of circulating monocytes as predictive biomarker of osteoclastogenesis in cf related bone disease. investigators will evaluate the presence and regulation of cd115 (mcsf receptor) and cd265 (rank) membrane receptors of circulating monocytes of cystic fibrosis patients. they will also analyze the impact of the f508del cftr mutation on the differentiation of monocytes into osteoclasts. we will 1) quantify the training and functional activity of osteoclasts and, 2) test in vitro the effects of correctors and potentiators of cftr on the resorption activity of differentiated osteoclasts. the study will be explained to patients and they only will have one blood test.

Eligibility criteria:
inclusion criteria: * patients with cystic fibrosis * attending the paris cochin adult cf centre * with at least f508del mutation (homozygote or heterozygote patients) exclusion criteria: * patients younger than 18 * absence of signed consent * patients without a f508del mutation

Keywords: cystic fibrosis cftr cftr modulators monocyte osteoclast osteoporosis
pioglitazone treatment for hyperglycemic acute ischemic stroke

Conditions: Stroke, Acute; Hyperglycemia; Diabetes

Summary: study objective is to determine whether pioglitazone (pgz) can improve clinical outcomes in hyperglycemic acute ischemic stroke (is). the rationale for the proposed research is to develop an acute intervention that can improve neurological recovery and decrease mortality and morbidity in high-risk diabetic stroke patients.

this is a prospective, randomized, double blinded stroke intervention study. patients presenting with hyperglycemia (blood glucose level = or \> than 150mg/dl) and acute stroke symptoms within 12h of onset will be randomized to either treatment with pgz or placebo. patients will receive oral drug vs placebo once daily for three consecutive days. blood samples will be obtained at baseline and during the subsequent three days to collect various biomarkers of the stress-immune response following ischemic stroke. clinical outcomes (nih-ss and mrs) will be determined at 3 months. secondary outcome measures are changes in the various blood biomarkers comparing both study groups.

Eligibility criteria:
inclusion criteria: 1. stroke patients ages 21 and over 2. blood sugar ≥ 150 mg/dl 3. study drug treatment should be initiated within 12 hours after time of symptom onset, if known, or the time last known normal (if time to symptom onset is unknown) 4. mri or ct proven ischemic stroke 5. initial nih ss of ≥ 2 6. willing and able to provide consent exclusion criteria: 1. known hypersensitivity to pgz. 2. infection at the time of presentation as defined by body temperature \> 38 degrees c , pneumonia evident on chest x-ray, urinary tract infection (positive tests for nitrites, leukocyte esterase, and bacteria on urine analysis), other acute infection per history or current use of antibiotic or antiviral treatment. 3. active malignancy and / or autoimmune disease requiring treatment. 4. use of immunomodulatory drugs or chemotherapy. 5. history of stroke or brain injury within the last 90 days prior to presentation. 6. acute illness within the last 30 days which could have affected the white blood cell count. 7. known history of clinically significant hypoglycemia. 8. patients already taking pgz. 9. active liver disease (alt and /or ast 2.5 times the upper limit of normal, total bilirubin \> 1.2 mg/dl). 10. acute decompensated heart failure, and/or admission for an acute coronary syndrome, myocardial infarction (mi), cardiac arrest, coronary artery surgery within the past 3 months and patients with new york heart association class iii and iv heart failure. 11. history of bladder cancer 12. pregnant and nursing women. 13. currently incarcerated patients.
the safety and effectiveness of nepa in preventing postoperative nausea and vomiting after general anesthesia gastrointestinal cancer surgery: a single-center retrospective study

Conditions: General Anesthesia Gastrointestinal Cancer Surgery

Summary: the rapid progress of multiple antiemetic regimens ensures that patients can receive full dose chemotherapy, however, there are still a large number of unmet clinical needs in patient evaluation and treatment. due to the fact that patients with liver, gallbladder, and pancreatic diseases undergoing surgery are still in the stage of nausea and vomiting, the actual incidence of delayed nausea and vomiting may be underestimated. the long-term effective control of nausea and vomiting by nitopitan palonosetron capsules may improve the quality of life of patients during and after treatment, and ultimately improve clinical outcomes


Eligibility criteria:
inclusion criteria: * 1. male or female, aged 18-65 years old; 2. the subjects were diagnosed with liver, gallbladder, and pancreatic diseases through histology or cytology and underwent elective surgical treatment, including but not limited to pancreaticoduodenectomy, liver resection, bile duct stone removal, etc., and received treatment with netopitam palonosetron capsules; 3. the subject is not in lactation period; 4. when screening female patients with potential pregnancy, it is necessary to confirm that the pregnancy test must be negative; 5. the subjects voluntarily and strictly comply with the research protocol requirements and sign a written informed consent form. exclusion criteria: * 1) serious liver and kidney dysfunction, cardiopulmonary dysfunction, or other serious diseases have not received standardized treatment; 2) having a serious mental illness in the past; 3) take antiemetics or antidepressants within 48 hours before surgery; 4) patients receiving systemic glucocorticoid treatment within 4 weeks prior to surgery; 5) take nk1 receptor antagonists or any investigational drugs within 4 weeks prior to the start of the experiment; 6) use cyp3a4 inducer within 4 weeks prior to surgery, and cyp3a4 substrate or potent, moderate cyp3a4 inhibitor within 1 week; 7) pregnant or lactating women, patients with fertility who are unwilling or unable to take effective contraceptive measures; 8) drug and/or alcohol abuse; 9) hypocalcemia or any other condition that may cause vomiting; 10) the subject has an allergic reaction to netopitam palonosetron capsules or any of their excipients; 11) participate in another clinical study within 30 days prior to baseline visit, using any exploratory drugs or devices; allow participation in observational research; 12) researchers assess other situations that may affect the progress of clinical research and the determination of research results.
adjuvant chemotherapy combined with targeted therapy or not in the t3-4n2 colorectal cancer patients

Conditions: Colorectal Cancer; Chemotherapy Effect

Summary: the goal of this clinical trial\] is to compare in resectable stage t3-4n2 colorectal cancer. the main question it aims to answer is: whether the use of targeted therapy in combination with adjuvant chemotherapy is associated with improved disease-free survival (dfs) compared to adjuvant chemotherapy alone.


Eligibility criteria:
inclusion criteria: 1. both sexes, aged 18-75 years; 2. pathologically confirmed pt3-4n2 stage colorectal adenocarcinoma after surgery; 3. asa grade \< iv and/or ecog performance status score ≤ 2 points; 4. fully understand and voluntarily sign the informed consent form for this study. exclusion criteria: 1. a history of other malignant tumors; 2. patients with severe liver, kidney, cardio-pulmonary, coagulation dysfunction, or underlying diseases that cannot tolerate chemotherapy; 3. patients allergic to any component in the study; 4. patients with severe uncontrollable recurrent infections or other severe uncontrollable concurrent diseases; 5. patients with other factors that may affect the study results or lead to premature termination of the study, such as alcoholism, drug abuse, other serious diseases requiring comprehensive treatment (including mental illness), and severe abnormalities in laboratory tests; 6. patients with emergent surgery due to intestinal obstruction, intestinal perforation, intestinal bleeding, etc.; 7. patients with a history of severe mental illness; 8. pregnant or lactating women; 9. patients with other clinical or laboratory conditions that the investigators consider inappropriate for participation in this trial.
theta-burst-stimulation in recurrent stroke recovery

Conditions: Stroke; Neurorehabilitation

Summary: the present study aims at investigating the effects of intermittent theta-burst stimulation (itbs) for motor recovery in recurrent stroke patients. therefore a daily intervention of repetitive transcranial magnetic stimulation over 8 days combined with subsequent physiotherapy is compared to a control condition, sham stimulation combined with subsequent physiotherapy. motor function, degree of disability and quality of life are examined in order to evaluate the effects of itbs in the rehabilitation of recurrent stroke patients in the first weeks and after three months.

to date, the majority of neuromodulation approaches aiming at improving motor recovery after stroke are limited to patients with first-ever ischemic stroke. therefore, rehabilitation of recurrent stroke mainly includes physiotherapy and occupational therapy. yet, particular these patients retain movement impairment relevant for activities of daily living. by using repetitive transcranial magnetic stimulation (rtms), it is possible to promote recovery of connectivity between brain regions, particularly after stroke and thereby improve motor performance. previous data indicate that intermittent theta-burst stimulation (itbs), a protocol of neuromodulation, enhances the effects of subsequent motor training in early rehabilitation after stroke. the current study aims at investigating whether daily repetitive transcranial magnetic stimulation over 8 days combined with subsequent physiotherapy leads to better motor recovery in recurrent stroke, compared to control condition, physiotherapy after sham stimulation. motor function, degree of disability and quality of life are examined in order to evaluate the effects of itbs in the rehabilitation of recurrent stroke patients in the first weeks and after three months.

Eligibility criteria:
inclusion criteria: * written consent * age: 40-90 years * recurrent stroke * hemiparesis with impaired hand motor function exclusion criteria: * subjects who are legally detained in an official institute (§20 mpg) * electronic implants or ferromagnetic implants located in the head, neck or thorax (e.g. clips, intracranial shunt, artificial heart valve, pacemaker) * medication pump (e.g. insulin pump) * metal splinters in eye or head * pregnancy / breastfeeding * severe neurodegenerative disease * severe neuroinflammatory disease * history of seizures / epilepsy * physical addiction to alcohol, medication, or drugs (excluded: nicotine) * insufficient compliance * present or past malignant tumor involving the central nervous system * severe psychiatric disease * frequent medication with benzodiazepines, high-potency antipsychotics or tricyclic antidepressants before hospitalization or long-term during hospitalization

Keywords: recurrent stroke stroke transcranial magnetic stimulation theta-burst-stimulation
proclaim registry to evaluate the treatment patterns and clinical response in malignancy

Conditions: Metastatic Renal Cell Carcinoma; Metastatic Melanoma

Summary: the purpose of this registry is to collect information on patients who are receiving treatment with proleukin in an organized way, and to learn more about patient care during and after treatment.

the proclaim registry is a us-based, multicenter registry designed to establish a high quality observational database of real-world clinical data on hd il-2 when used to treat patients with mrcc, mm or other malignancies. the registry will not, in any way, suggest changes in the treatment or management of the patients enrolled in the registry. therefore, physicians will continue to manage and treat patients according to standard of care and their own judgment. the proclaim registry will start with a retrospective pilot data collection from a de-identified finite number of patient cases abstracted from their existing medical charts. the features collected will be identical to those planned for the prospective registry. the resulting database will be used to formulate hypotheses to be tested using the prospective registry database. patients utilized in the retrospective analysis will be excluded from the prospective portion of the registry. in the prospective portion of the registry, sites will enroll patients who are expected to start a course of hd il-2 therapy. once enrolled, the patient must receive at least one dose of hd il-2 to remain in the registry. patients will be treated and followed according to the site's standard of care. this registry will in no way induce changes in the management of individual patients. clinical data features will be entered into an electronic data capture (edc) system, and organized into a registry database. the data contained in the registry database will be observational data. the proclaim registry does not stipulate patient care, specific visits or interventions but merely surveys standardized parameters regarding hd il-2 and associated therapies as they are applied by treatment centers. the collection of standard data over time permits the evaluation of trends in patient survival and subsequent therapy exposure. the database will be used to answer future queries formulated by researchers.

Eligibility criteria:
inclusion criteria: * 18 years or older * must have received at least one course of high dose il-2 or proleukin * signed informed consent form exclusion criteria: * prior high dose il-2 or proleukin therapy
prolonged cardiopulmonary bypass time as predictive factor for in hospital infection

Conditions: Bloodstream Infection (BSI)

Summary: this study is to analyse the demographics and microbiological factors concerning patients undergoing cardio surgical intervention using cpb complicated with bloodstream infection (bsi) postoperatively.

infectious complications after cardiovascular surgery, especially in operations that use cardiopulmonary bypass (cpb), is associated with significant morbidity and increase in peri-operative mortality. prolonged cpb usage could be predictive for early bloodstream infection following cardia surgery. this study is to analyse the demographics and microbiological factors concerning patients undergoing cardio surgical intervention using cpb complicated with bloodstream infection (bsi) postoperatively.

Eligibility criteria:
inclusion criteria: * adult patients undergoing cardiac surgery exclusion criteria: * patients having active or previous endocarditis * patients whose causative microorganism of postoperative bsi was identical to that isolated from preoperative or intraoperative samples * patients with common skin colonized microorganisms, such as coagulase-negative staphylococci, viridans group streptococci, corynebacterium species, bacillus species, propionibacterium species, and aerococcus species or micrococcus species, which were isolated from only a single blood sample and without evidence of clinical sepsis, because contamination was considered.

Keywords: cardiovascular surgery cardiopulmonary bypass (cpb) nosocomial infection early bloodstream infection postoperative septicaemia